HNP yields 120.53% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, HNP + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HNP + PFE for your $10,000?
Huaneng Power International, Inc., together with its subsidiaries, engages in the generation and sale of electric power to the regional or provincial grid companies in the People's Republic of China and internationally. It is involved in the development, construction, operation, and management of power plants and related projects. The company also generates power from gas turbine, hydro, wind, photovoltaic, coal-fired, and biomass resources. In addition, it is involved in the sale of coal ash and lime; cargo loading and storage; port, warehousing, and conveying activities; photovoltaic power generation projects development and construction; and provision of thermal energy and cold energy services, as well as thermal heating services. Further, the company engages in the repair and maintenance of power equipment; supply of steam and hot water; plumbing pipe installation and repair; and energy engineering construction activities. Additionally, it is involved in the provision of transportation services; construction and operation of electricity distribution networks and heating pipe networks; energy supply, energy transmission, and substation project contracting activities; cargo handling and transportation; and port management, investment, and development activities. The company engages in the management of industrial water and waste, as well as provides environment engineering, and information technology and management consulting services. It also sells raw and processed coal; and offers central heat and desalinated water services. As of December 31, 2021, the company had a controlled generating capacity of 118,695 megawatts and an equity-based installed capacity of 103,875 megawatts. Huaneng Power International, Inc. was incorporated in 1994 and is based in Beijing, the People's Republic of China.
Full HNP Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.